{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:33:11Z","timestamp":1789702391533,"version":"4.0.1"},"reference-count":63,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,17]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Bulk sequencing of relapsed tumors reveals mutations associated with resistance to cancer therapy but is insufficient to fully assess all causes of relapse. Because of inherent tumor heterogeneity, on-treatment tumor evolution may select genetically distinct clones or shifts in malignant transcriptional states not resolvable by bulk sequencing. We performed multiomic single-cell DNA\/protein and RNA\/protein profiling of a clinical trial cohort of patients with acute myeloid leukemia (AML) treated on the phase 1b clinical trial of the BCL2 inhibitor venetoclax and the FLT3 inhibitor gilteritinib (Ven\/Gilt) to characterize immunophenotypic, transcriptional, and genetic clonal evolution driving resistance. We found that although Ven\/Gilt effectively eliminated FLT3-mutant clones, resistance was associated with RAS activation through multiple mechanisms, including selection for RAS-mutant clones, nonmutational upregulation of RAS transcriptional programs, and a shift to RAS-associated monocytic AML differentiation. Using an in vitro model of monocytic differentiation associated with nonmutational RAS transcriptional activation, we demonstrated that RAS-pathway inhibition resensitized to Ven\/Gilt. These data illustrate that convergent resistance pathways in patients can be activated via diverse genetic and nongenetic mechanisms. These results underscore that RAS signaling is central to FLT3 and BCL2 inhibitor resistance, is tightly coupled with AML monocytic differentiation, and highlights the potential of RAS-pathway inhibition as a viable clinical strategy to combat resistance. This trial was registered at www.ClinicalTrials.gov as NCT03625505.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032466","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:01:41Z","timestamp":1780336901000},"page":"1588-1604","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1912-4076","authenticated-orcid":false,"given":"Vanessa E.","family":"Kennedy","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Stanford University, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl A. C.","family":"Peretz","sequence":"additional","affiliation":[{"name":"2Division of Hematology\/Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4958-4409","authenticated-orcid":false,"given":"Anushka","family":"Walia","sequence":"additional","affiliation":[{"name":"3Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Chyla","sequence":"additional","affiliation":[{"name":"4AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7856-7195","authenticated-orcid":false,"given":"Yan","family":"Sun","sequence":"additional","affiliation":[{"name":"4AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2512-1661","authenticated-orcid":false,"given":"Jason","family":"Hill","sequence":"additional","affiliation":[{"name":"5Astellas Pharma Global Development, Inc, Northbrook, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5370-7788","authenticated-orcid":false,"given":"Elaine","family":"Tran","sequence":"additional","affiliation":[{"name":"3Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Koh","sequence":"additional","affiliation":[{"name":"3Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Ferng","sequence":"additional","affiliation":[{"name":"3Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Pintar","sequence":"additional","affiliation":[{"name":"3Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F.","family":"Jones","sequence":"additional","affiliation":[{"name":"3Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7960-5218","authenticated-orcid":false,"given":"Bogdan","family":"Popescu","sequence":"additional","affiliation":[{"name":"3Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4327-2997","authenticated-orcid":false,"given":"Isabelle","family":"Lomeli","sequence":"additional","affiliation":[{"name":"3Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Chehab","sequence":"additional","affiliation":[{"name":"6Department of Pathology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Murad","sequence":"additional","affiliation":[{"name":"3Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4615-9474","authenticated-orcid":false,"given":"August","family":"John","sequence":"additional","affiliation":[{"name":"3Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2065-7846","authenticated-orcid":false,"given":"Ritu","family":"Roy","sequence":"additional","affiliation":[{"name":"7Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Olshen","sequence":"additional","affiliation":[{"name":"7Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4657-2376","authenticated-orcid":false,"given":"Christine A.","family":"Berryhill","sequence":"additional","affiliation":[{"name":"8Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Davis","sequence":"additional","affiliation":[{"name":"8Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7655-657X","authenticated-orcid":false,"given":"Steven P.","family":"Angus","sequence":"additional","affiliation":[{"name":"8Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Rivera","sequence":"additional","affiliation":[{"name":"2Division of Hematology\/Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Meshulam","sequence":"additional","affiliation":[{"name":"2Division of Hematology\/Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7032-4623","authenticated-orcid":false,"given":"Elliot","family":"Stieglitz","sequence":"additional","affiliation":[{"name":"2Division of Hematology\/Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2798-5762","authenticated-orcid":false,"given":"Sunil","family":"Joshi","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Stanford University, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8844-2345","authenticated-orcid":false,"given":"Elie","family":"Traer","sequence":"additional","affiliation":[{"name":"9Department of Medicine, Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Dail","sequence":"additional","affiliation":[{"name":"10Genentech Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Hamidi","sequence":"additional","affiliation":[{"name":"10Genentech Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Altman","sequence":"additional","affiliation":[{"name":"11Division of Hematology\/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"12Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0473-6982","authenticated-orcid":false,"given":"Mark","family":"Levis","sequence":"additional","affiliation":[{"name":"13Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McCloskey","sequence":"additional","affiliation":[{"name":"14Department of Leukemia, John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-2231","authenticated-orcid":false,"given":"Alexander E.","family":"Perl","sequence":"additional","affiliation":[{"name":"15Division of Hematology\/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Smith","sequence":"additional","affiliation":[{"name":"3Division of Hematology\/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2026091711213828400_bib1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.2021014901","article-title":"Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed\/refractory AML: a randomized phase 3 trial","volume":"141","author":"de Botton","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2026091711213828400_bib2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"2026091711213828400_bib3","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am J Hematol"},{"issue":"25","key":"2026091711213828400_bib4","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"2026091711213828400_bib5","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1038\/s41375-021-01179-4","article-title":"Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603\/RATIFY trial","volume":"35","author":"Larson","year":"2021","journal-title":"Leukemia"},{"issue":"18","key":"2026091711213828400_bib6","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"2026091711213828400_bib7","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood.2021011583","article-title":"Follow-up of patients with R\/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial","volume":"139","author":"Perl","year":"2022","journal-title":"Blood"},{"issue":"35","key":"2026091711213828400_bib8","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026091711213828400_bib9","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"2026091711213828400_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"2026091711213828400_bib11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2026091711213828400_bib12","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","article-title":"Molecular profile of FLT3-mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib","volume":"6","author":"Smith","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"2026091711213828400_bib13","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","article-title":"Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response","volume":"130","author":"Amatangelo","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2026091711213828400_bib14","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","article-title":"Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML","volume":"4","author":"Choe","year":"2020","journal-title":"Blood Adv"},{"key":"2026091711213828400_bib15","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/bloodadvances.2020003398","article-title":"Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib","volume":"5","author":"Peretz","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2026091711213828400_bib16","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanmaki","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"2026091711213828400_bib17","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"8","key":"2026091711213828400_bib18","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","article-title":"Integrative analysis of drug response and clinical outcome in acute myeloid leukemia","volume":"40","author":"Bottomly","year":"2022","journal-title":"Cancer Cell"},{"issue":"1","key":"2026091711213828400_bib19","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41467-021-21810-3","article-title":"Joint profiling of DNA and proteins in single cells to dissect genotype-phenotype associations in leukemia","volume":"12","author":"Demaree","year":"2021","journal-title":"Nat Commun"},{"issue":"9","key":"2026091711213828400_bib20","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1101\/gr.232272.117","article-title":"High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics","volume":"28","author":"Pellegrino","year":"2018","journal-title":"Genome Res"},{"issue":"5","key":"2026091711213828400_bib21","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"16","key":"2026091711213828400_bib22","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2012-07-442871","article-title":"Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD","volume":"121","author":"Smith","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2026091711213828400_bib23","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.molcel.2008.07.007","article-title":"Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle","volume":"31","author":"Daub","year":"2008","journal-title":"Mol Cell"},{"issue":"2","key":"2026091711213828400_bib24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cell.2012.02.053","article-title":"Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer","volume":"149","author":"Duncan","year":"2012","journal-title":"Cell"},{"issue":"1","key":"2026091711213828400_bib25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41591-020-01193-6","article-title":"Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial","volume":"27","author":"Fisher","year":"2021","journal-title":"Nat Med"},{"issue":"24","key":"2026091711213828400_bib26","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026091711213828400_bib27","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-018-0115-6","article-title":"Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib","volume":"24","author":"Quek","year":"2018","journal-title":"Nat Med"},{"key":"2026091711213828400_bib28","doi-asserted-by":"crossref","first-page":"E364","DOI":"10.1002\/ajh.27096","article-title":"The FLT3(N701K) mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib","volume":"98","author":"Joshi","year":"2023","journal-title":"Am J Hematol"},{"key":"2026091711213828400_bib29","doi-asserted-by":"crossref","first-page":"E226","DOI":"10.1002\/ajh.26174","article-title":"A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance","volume":"96","author":"Joshi","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"2026091711213828400_bib30","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1182\/bloodadvances.2019000919","article-title":"Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations","volume":"4","author":"Tarver","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2026091711213828400_bib31","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","article-title":"A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy","volume":"13","author":"Pei","year":"2023","journal-title":"Cancer Discov"},{"issue":"10","key":"2026091711213828400_bib32","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"2026091711213828400_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.blre.2018.10.003","article-title":"Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia","volume":"34","author":"Morsink","year":"2019","journal-title":"Blood Rev"},{"issue":"1","key":"2026091711213828400_bib34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.5858\/2010-0387-RAR.1","article-title":"Multiparameter flow cytometry in the diagnosis and management of acute leukemia","volume":"135","author":"Peters","year":"2011","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"2026091711213828400_bib35","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2020006921","article-title":"CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy","volume":"137","author":"Willier","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2026091711213828400_bib36","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"issue":"6476","key":"2026091711213828400_bib37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1126\/science.aax0249","article-title":"Single-cell transcriptional diversity is a hallmark of developmental potential","volume":"367","author":"Gulati","year":"2020","journal-title":"Science"},{"issue":"9","key":"2026091711213828400_bib38","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.leu.2404808","article-title":"Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias","volume":"21","author":"Mullighan","year":"2007","journal-title":"Leukemia"},{"issue":"12","key":"2026091711213828400_bib39","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2004-03-1154","article-title":"Gene expression profiling of pediatric acute myelogenous leukemia","volume":"104","author":"Ross","year":"2004","journal-title":"Blood"},{"issue":"7834","key":"2026091711213828400_bib40","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"issue":"12","key":"2026091711213828400_bib41","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular signatures database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"issue":"6","key":"2026091711213828400_bib42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"issue":"5","key":"2026091711213828400_bib43","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1158\/2643-3230.BCD-24-0256","article-title":"Genetic and phenotypic correlates of clinical outcomes with venetoclax in acute myeloid leukemia: the GEN-PHEN-VEN Study","volume":"6","author":"Lachowiez","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"2026091711213828400_bib44","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"2026091711213828400_bib45","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s42003-023-05013-8","article-title":"Molecular and cellular evidence for the impact of a hypertrophic cardiomyopathy-associated RAF1 variant on the structure and function of contractile machinery in bioartificial cardiac tissues","volume":"6","author":"Nakhaei-Rad","year":"2023","journal-title":"Commun Biol"},{"issue":"6","key":"2026091711213828400_bib46","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2026091711213828400_bib47","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood.2025030558","article-title":"Multi-selective RAS(ON) inhibition targets oncogenic RAS mutations and overcomes RAS\/MAPK-mediated resistance to FLT3 and BCL2 inhibitors in acute myeloid leukemia","volume":"147","author":"Popescu","year":"2026","journal-title":"Blood"},{"issue":"suppl 1","key":"2026091711213828400_bib48","article-title":"The FLT3-like gene expression signature predicts response to quizartinib in wild-type FLT3 acute myeloid leukemia: an analysis of the Pethema Quiwi Trial","volume":"142","author":"Mosquera Orgueira","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026091711213828400_bib49","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2024-201264","article-title":"Enhanced validation of the FLT3-like gene expression signature as a predictive biomarker for quizartinib response in FLT3-ITD negative acute myeloid leukemia: expanded cohort and extended follow-up from the Pethema Quiwi Trial","volume":"144","author":"Mosquera Orgueira","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2026091711213828400_bib50","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"suppl 1","key":"2026091711213828400_bib51","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1182\/blood-2023-190801","article-title":"A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3\/IDH1 or FLT3\/IDH2 mutations","volume":"142","author":"Stein","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026091711213828400_bib52","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2024-208953","article-title":"Haplo-insufficiency of RAS genes is the determinant of outcome in AML","volume":"144","author":"Peplinski","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026091711213828400_bib53","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1158\/0008-5472.CAN-23-2709","article-title":"KRAS loss of heterozygosity promotes MAPK-dependent pancreatic ductal adenocarcinoma initiation and induces therapeutic sensitivity to MEK inhibition","volume":"85","author":"Fey","year":"2025","journal-title":"Cancer Res"},{"issue":"5","key":"2026091711213828400_bib54","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1365-2141.2005.05685.x","article-title":"Differences in the prevalence of PTPN11 mutations in FAB M5 paediatric acute myeloid leukaemia","volume":"130","author":"Goemans","year":"2005","journal-title":"Br J Haematol"},{"key":"2026091711213828400_bib55","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"issue":"1","key":"2026091711213828400_bib56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41698-021-00209-9","article-title":"Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia","volume":"5","author":"White","year":"2021","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"2026091711213828400_bib57","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood.2025030558","article-title":"Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML","volume":"147","author":"Popescu","year":"2026","journal-title":"Blood"},{"issue":"5","key":"2026091711213828400_bib58","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1158\/2643-3230.BCD-21-0012","article-title":"Monocytic differentiation and AHR signaling as primary nodes of BET inhibitor response in acute myeloid leukemia","volume":"2","author":"Romine","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2026091711213828400_bib59","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1038\/s41598-019-45982-7","article-title":"Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells","volume":"9","author":"Huynh","year":"2019","journal-title":"Sci Rep"},{"issue":"7954","key":"2026091711213828400_bib60","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"12","key":"2026091711213828400_bib61","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41408-021-00584-3","article-title":"Differentiation therapy for myeloid malignancies: beyond cytotoxicity","volume":"11","author":"Stubbins","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"2026091711213828400_bib62","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41375-023-02131-4","article-title":"FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia","volume":"38","author":"Sung","year":"2024","journal-title":"Leukemia"},{"issue":"10","key":"2026091711213828400_bib63","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/bloodadvances.2018029496","article-title":"Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia","volume":"3","author":"McMahon","year":"2019","journal-title":"Blood Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/12\/1588\/2588648\/blood_bld-2025-032466-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/12\/1588\/2588648\/blood_bld-2025-032466-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:21:48Z","timestamp":1789658508000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/12\/1588\/568816\/Dynamic-genetic-and-nongenetic-RAS-pathway"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":63,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,9,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032466","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,17]]},"published":{"date-parts":[[2026,9,17]]}}}